Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Carcinoma in Situ

Uterine Cervical Dysplasia

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Precancerous Conditions

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Cervical Intraepithelial Neoplasia

Surgery with Large Loop Excision of Transformation Zone (LLETZ)

Excision of the lesion

Follow-up for spontaneous regression of the lesion

Sylvia F Brenna, MD, PhD

Ana C Guedes, MD, PhD

Kari J Sirjanen, MD, PhD

Luis C Zeferino, MD, PhD

The aim of this study was to compare two management options for CIN 2. This randomized clinical trial performed between 2003 and 2006. A series of 90 Brazilian women diagnosed as CIN2 were randomized into two groups: 1) 45 whose lesion was excised and,2) 45 women subjected to follow-up at 3-month intervals for 12 months.

Pap smear and colposcopy were performed at every follow-up visit and all lesions were completely visible at colposcopy.

The researchers purpose was to make some comments about the over treatment and the misclassification of CIN 2.

Management of Cervical Intraepithelial Neoplasia Grade 2

Fundação de Amparo à Pesquisa do Estado de São Paulo

Universidade Cidade de Sao Paulo

Jose Lucio Martins Machado

Symptoms and General Pathology

Behaviors and Mental Disorders

Ascites

Quality of Life

Patients with malignant, symptomatic, refractory ascites. Ascites drainage with vascular catheter (CVC) inserted into abdominal cavity will be performed. Patients will be asked to complete interview, quality of life questionnaire, nutritional status assessment and quality of procedure survey.

In case of symptomatic malignant ascites, the procedure of vascular catheter insertion into abdominal cavity will be performed, followed by slow, systematic drainage, on patient's demand.

Ascites drainage with vascular catheter.

Interview with patients will be performed according to attached chart. The aim is to collect data concerning patient's symptoms, co-morbidity, and basic clinical data about the primary malignancy and treatment status.

Interview.

Quality of life questionnaire (QLQ). Patients will be asked to complete QLQ at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.

Quality of life.

Patients will be asked to complete quality of procedure questionnaire at one time point: one or two weeks after the procedure.

Quality of procedure.

Risk of malnutrition and ability to feed normally will be assessed with specific questionnaire at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.

Nutritional status

Maciej Stukan, MD

Ivana Nohova

The purpose of this study is to determine whether drainage with the usage of a fine, patient-controlled vascular catheter inserted into abdominal cavity is a feasible, safe and effective method in the management of symptomatic malignant ascites. Complications' rate of the procedure and patients' quality of life, nutritional status and experience on the treatment are main endpoints.

Patients with symptomatic, refractory malignant ascites (MA) will be eligible for the study. In case a cancer treatment is not effective against ascites, or no target, systemic treatment is possible patients will be eligible for percutaneous placement of a vascular catheter into abdominal cavity followed be drainage performed in a regular basis when required, at home or ambulatory. Adult patients with every malignant disease, female and male, and coexisting symptomatic MA can be recruited.

Clinical, quality of life (QOL) and quality of the procedure data will be collected. The study is planned to be a multiinstitutional. A template is provided to collect essential clinical data concerned with a patient, malignant disease, procedure performance and complications. QOL and patients' experience on the treatment is to be evaluated with formal questionnaires - EORTC C15-PAL and FACIT-TS-G - permission to use granted from EORTC and FACIT respectively. Additionally, a nutrition monitoring will be performed (if possible and feasible) in patients with MA and drainage.

Data will be saved in a computer, secured data base for calculations. A cohort of 150 patients is planned to be collected. Duration of the study will depend on how many institutions will participate, and how fast patients will be recruited.

Symptomatic Ascites Drainage With a Patient-controlled Vascular Catheter.

Management of Symptomatic Malignant Ascites With an Patient-controlled, Vascular Catheter - a Validation Study.

Risk of malnutrition and ability to feed normally to be assessed with Subjective Global Assessment (SGA) questionnaire among participants with prolonged (1-2 months) ascites drainage.

Number of ambulatory visits or hospital admissions to manage symptoms caused by ascites.

Early and late adverse events of the catheter placement and later drainage to be recorded.

Change in quality of life measured with standard questionnaire EORTC-C15-PAL before the procedure and 1-2 weeks later.

Assessment of possibilities to provide cancer treatment with active ascites drainage via catheter, by reporting number of participants with adverse events during chemotherapy or radiotherapy, whichever applies and comparison to observation (patients with palliative intent only, no active cancer treatment).

From all eligible participants a number of participants with successful catheter placement followed by effective drainage will be recorded.

Patient's experience on the treatment measured with standard questionnaire (FACIT-TS-G).

Changes in ability to feed assessed in a descriptive way with the Subjective Global Assessment (SGA) questionnaire.

Maciej Stukan, MD, PhD

Nutritional and Metabolic Diseases

Malnutrition

Wasting Syndrome

Cachexia

Syndrome

Nutrition Disorders

Weight Loss

Body Weight

Body Weight Changes

Thinness

Metabolic Diseases

12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires.

12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.

Multimodal education and support program for cancer related cachexia prevention

Andreas Charalambous, PhD

Constantina Cloconi, MSc

The aim of the study is to evaluate the effectiveness of a multifactorial education and support program for the prevention of cancer-related cachexia syndrome, for patients and their family caregivers during anti-cancer treatment.

After being informed about the study and the need to nominate a family caregiver, all patients and their family caregiver giving written informed consent, they will undergo a 12-weeks multimodal program. Randomly they will divided into two groups (intervention and control). This 12-weeks multimodal program includes 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management.

Multimodal Program for Cancer Related Cachexia Prevention

Effectiveness of a Multimodal Education and Support Program for the Prevention of Cancer Related Cachexia for Patients and Their Family Caregiver

To assess the patient's baseline cancer cachexia stage with weight (weight loss \<5% in previous three months, kg), height (cm) and BMI (BMI \> 20) measurements.

Blood test for C-reactive protein (mg/L). CRP level greater than 10 mg/L is a sign of active inflammation.

Blood test for Albumin Levels. normal ranges \>35g/L

Participants will fill the questionnaire at baseline and at week 12 to compare the score of FAACT.

The FAACT questionnaire is validated, self-reported instrument (28-item) assessing the quality of life of cancer patients with any tumour type. Possible scores range from 0 (lower quality of life) to 112 (better quality of life).

Change = Week 12 - Baseline

Participants will fill the questionnaire at week 4 and at week 12 to compare the score of CarGOQoL.

The CarGOQoL questionnaire is validated, self-reported instrument (29 items investigating 10 domains) assessing the quality of life of family caregivers. Possible scores range from 0 (lower quality of life) to 100 (better quality of life).

Change = Week 12 - Week 4

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Management of Cervical Intraepithelial Neoplasia Grade 2	NCT00733109	Cervical Intrae...	Excision of the... Follow-up for s...	18 Years - 61 Years	Universidade Cidade de Sao Paulo
Symptomatic Ascites Drainage With a Patient-controlled Vascular Catheter.	NCT02724683	Malignant Ascit...	Ascites drainag... Interview. Quality of life... Quality of proc... Nutritional sta...	18 Years -	Gdynia Oncology Center
Multimodal Program for Cancer Related Cachexia Prevention	NCT04627376	Neoplasms Cancer Cachexia Malnutrition Educational Pro...	Multimodal educ...	18 Years -	Cyprus University of Technology

Spots Global Cancer Trial Database for management

Every month we try and update this database with for management cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for management

Every month we try and update this database with for management cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for management cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.